Quantcast
Home > Quotes > SBOT

Stellar Biotechnologies, Inc. Common Shares (SBOT) Quote & Summary Data

SBOT 
$1.84
*  
0.05
2.79%
Get SBOT Alerts
*Delayed - data as of Jun. 15, 2018  -  Find a broker to begin trading SBOT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
19.497
Today's High / Low
$ 1.84 / $ 1.7699
Share Volume
75,970
50 Day Avg. Daily Volume
713,651
Previous Close
$ 1.79
52 Week High / Low
$ 10.85 / $ 1.72
Market Cap
8,681,889
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.19

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
May 7, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
75,970
50 Day Avg. Daily Volume:
713,651

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.36

Trading Range

The current last sale of $1.84 is 6.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.84 $ 10.85
 Low: $ 1.7699 $ 1.72

Company Description (as filed with the SEC)

Stellar Biotechnologies, Inc. is a biotechnology company engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein with an extensive history of safe and effective use in immunological applications. Immunotherapies (also known as therapeutic vaccines) are an emerging class of treatments that involve using the body's own immune system to target and treat disease. Today, multiple companies and institutions are developing drugs that combine disease-targeting agents with KLH. These disease-targeting agents do not evoke a robust immune response by themselves and thus require a carrier molecule like KLH. The versatility of the KLH molecule and its use in multiple drug development pipelines provide numerous commercial opportunities for us.  ... More ...  

Risk Grade

Where does SBOT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.81
Open Date:
Jun. 15, 2018
Close Price:
$ 1.84
Close Date:
Jun. 15, 2018

Consensus Recommendation

Analyst Info